Last reviewed · How we verify
YKST02
At a glance
| Generic name | YKST02 |
|---|---|
| Also known as | YKST02 for Injection |
| Sponsor | Excyte Biopharma Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of YKST02 in Participants With Primary IgA Nephropathy (EARLY_PHASE1)
- A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YKST02 CI brief — competitive landscape report
- YKST02 updates RSS · CI watch RSS
- Excyte Biopharma Ltd portfolio CI